Company intelligence / Profile preview

Novita Distribuição, Armazenamento e Transportes

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

NP-G2-044, Novita’s small-molecule fascin inhibitor, has shown durable responses and safety in Phase 2 clinical trials for advanced and metastatic solid tumors both as monotherapy and in combination with anti-PD-1 agents. Over half of treated patients showed no new metastases; several patients achieved complete responses in difficult-to-treat cancers. No new safety signals observed; further expansion cohorts and Phase 3 study (ovarian cancer) planned.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Novita Distribuição, Armazenamento e Transportes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novita Distribuição, Armazenamento e Transportes.

Explore the full profile